Attovia Therapeutics, Inc. (ATTO) dividends
ATTO on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Attovia Therapeutics, Inc. dividend: key facts
Own Attovia Therapeutics, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next ATTO dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Results, reports and dividend announcements
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Attovia price target raised to $34 from $30 at Citi11 Nov 2026 · TheFly
Citi analyst Yigal Nochomovitz raised the firmâs price target on Attovia (ATTO) to $34 from $30 and keeps a Buy rating on the shares.
- Attovia price target raised to $40 from $39 at Morgan Stanley10 Nov 2026 · TheFly
Morgan Stanley raised the firmâs price target on Attovia (ATTO) to $40 from $39 and keeps an Overweight rating on the shares.
- Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update10 Nov 2026 · GlobeNewsWire
Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase 2 trials of ATTO-1310 in patien...
- Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis6 Nov 2026 · GlobeNewsWire
Results build on preliminary Week 4 findings, in which a single dose of ATTO-1310 demonstrated rapid, deep, and durable itch relief in patients with chronic pruritus (CP) and high-itch atopic dermatit...
- Attovia Therapeutics to Participate in Upcoming Investor Conferences28 Oct 2026 · GlobeNewsWire
SAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (âAttoviaâ or the âCompanyâ) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biot...
- Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 20263 Oct 2026 · GlobeNewsWire
SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (âAttoviaâ) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for ...
- Attovia reports Q2 EPS ($4.88), consensus ($4.61)15 Sep 2026 · TheFly
âFollowing the successful completion of our upsized IPO, Attovia (ATTO) enters its next exciting phase with a strong balance sheet and clear line of sight to multiple potential near-term value-creatin...
- Attovia initiated with an Overweight at Morgan Stanley15 Sep 2026 · TheFly
Morgan Stanley initiated coverage of Attovia (ATTO) with an Overweight rating and $39 price target The companyâs focus on âde-risked targetsâ positions it path to blockbuster opportunities in chronic ...
Insufficient verified data for a financial-health score
Dividend data and price last updated 17 Nov 2026.